Quintiles Transitional Holdings (NYSE:Q) Analyst Rating Consensus

Quintiles Transitional Holdings (NYSE:Q) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.65 by 13 Brokerage Firm. 8 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating. 4 Brokerage Firms have advised hold.

Other Equity analysts have also commented on the company shares. Wells Fargo downgrades its rating on Quintiles Transitional Holdings (NYSE:Q). Analysts at the Wells Fargo have a current rating of Market Perform on the shares. The shares were previously rated Outperform. The rating by the firm was issued on May 12, 2016.

Quintiles Transitional Holdings (NYSE:Q) shares are expected to touch $75.05 in the short term. This short term price target has been shared by 10 analysts. However, the standard deviation of short term price estimate has been valued at 6.26. The target price could hit $83 on the higher end and $62 on the lower end.

Quintiles Transitional Holdings (NYSE:Q) rose 0.22% or 0.14 points on Tuesday and made its way into the gainers of the day. After trading began at $64.01 the stock was seen hitting $64.1 as a peak level and $63.66 as the lowest level. The stock ended up at $63.83. The daily volume was measured at 967,247 shares. The 52-week high of the share price is $80.45 and the 52-week low is $55.011. The company has a market cap of $7,638 million.

Quintiles Transnational Holdings Inc. has lost 2.06% in the last five trading days and dropped 4.09% in the last 4 weeks. Quintiles Transnational Holdings Inc. has dropped 2.25% during the last 3-month period . Year-to-Date the stock performance stands at -7.03%.

Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic, scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services, such as phase research, market access and consulting, and health information analytics and technology consulting.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *